Why Bausch + Lomb Stock Soared by Over 7% on Monday

Core Insights - Bausch + Lomb experienced a significant day with FDA approval and reports of a potential sale, leading to a stock price increase of over 7% [1] Group 1: FDA Approval - The FDA granted approval for Bausch + Lomb's full range of enVista Envy vision intraocular lenses (IOLs), which are used to treat cataracts and other vision disorders [4] Group 2: Potential Sale - Reports indicate that Bausch + Lomb is exploring a sale, with large U.S. investment firms Blackstone and TPG potentially collaborating on a buyout bid [2] - Bids for Bausch + Lomb are expected to range from $13 billion to $14 billion in enterprise value [3] - The management is working with advisor Goldman Sachs to gauge interest from potential buyers [2]